Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …

Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin,
and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or …

High-grade serous ovarian carcinoma (HGSOC) is genetically unstable and characterised
by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked …

Chemotherapy resistance is a critical contributor to cancer mortality and thus an urgent
unmet challenge in oncology. To characterize chemotherapy resistance processes in high …

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers
(HGSCs) survive more than five years after diagnosis, but those who have an exceptionally …

Abstract ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP
inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous
recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to …

High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths,
and overall survival has not changed significantly for several decades. In this Opinion article …

Patients with high-grade serous ovarian cancer (HGSC) have experienced little
improvement in overall survival, and standard treatment has not advanced beyond platinum …